Well-differentiated thyroid carcinoma: The role of post-operative radioactive iodine administration

Journal of Surgical Oncology

Volumn 107, Issue 6, 2013, Pages 665-672

  Patel, Supriya S ^a   Goldfarb, Melanie ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

ablation; differentiated thyroid cancer; radioiodine

Indexed keywords

RADIOACTIVE IODINE; THYROTROPIN;

CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; DIFFERENTIATED THYROID CANCER; DISEASE FREE SURVIVAL; EVIDENCE BASED PRACTICE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LOW RISK POPULATION; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; META ANALYSIS (TOPIC); OVERALL SURVIVAL; POSTOPERATIVE CARE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURGEON; THYROIDECTOMY; THYROTROPIN BLOOD LEVEL;

ABLATION TECHNIQUES; ADENOCARCINOMA, FOLLICULAR; AGE FACTORS; CARCINOMA; HUMANS; IODINE RADIOISOTOPES; NEOPLASM RECURRENCE, LOCAL; PATIENT SELECTION; RADIATION DOSAGE; RADIOPHARMACEUTICALS; RADIOTHERAPY, ADJUVANT; THYROID NEOPLASMS; THYROIDECTOMY; TREATMENT OUTCOME;

EID: 84876411639     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23295     Document Type: Review

References (79)

1. Martinez Trufero J, Capdevilla J, Cruz JJ, et al.: SEOM clinical guidelines for the treatment of thyroid cancer. Clin Transl Oncol 2011; 13: 574-579.
2. Jonklaas J, Sarlis NJ, Litofsky D, et al.: Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006; 16: 1229-1242.
3. Van Nostrand D:, The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer. Thyroid 2009; 19: 1381-1391.
4. Hundahl SA, Fleming ID, Fremgen AM, et al.: A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]. Cancer 1998; 83: 2638-2648.
5. Hay ID, Thompson GB, Grant CS, et al.: Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): Temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 2002; 26: 879-885.
6. Lundgren CI, Hall P, Dickman PW, et al.: Influence of surgical and postoperative treatment on survival in differentiated thyroid cancer. Br J Surg 2007; 94: 571-577.
7. Pacini F, Schlumberger M, Harmer C, et al.: Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: A consensus report. Eur J Endocrinol 2005; 153: 651-659.
8. Cooper DS, Doherty GM, Haugen BR, et al.: Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-1214.
9. Tuttle RM, Ball DW, Byrd D, et al.: Thyroid carcinoma. J Natl Compr Canc Netw 2010; 8: 1228-1274.
10. Sawka AM, Straus S, Brierley JD, et al.: Decision aid on radioactive iodine treatment for early stage papillary thyroid cancer-A randomized controlled trial. Trials 2010; 11: 81.
11. Sawka AM, Straus S, Gafni A, et al.: A usability study of a computerized decision aid to help patients with, early stage papillary thyroid carcinoma in, decision-making on adjuvant radioactive iodine treatment. Patient Educ Couns 2011; 84: e24-e27.
12. Mazzaferri EL:, Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma. Thyroid 1997; 7: 265-271.
13. Sanders LE, Cady B:, Differentiated thyroid cancer: Reexamination of risk groups and outcome of treatment. Arch Surg 1998; 133: 419-425.
14. Brierley J, Tsang R, Panzarella T, et al.: Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years. Clin Endocrinol 2005; 63: 418-427.
15. Kim S, Wei JP, Braveman JM, et al.: Predicting outcome and directing therapy for papillary thyroid carcinoma. Arch Surg 2004; 139: 390-394; discussion 393-394.
16. Haymart MR, Banerjee M, Stewart AK, et al.: Use of radioactive iodine for thyroid cancer. JAMA 2011; 306: 721-728.
17. Sawka AM, Rotstein L, Brierley JD, et al.: Regional differences in opinions on adjuvant radioactive iodine treatment of thyroid carcinoma within Canada and the United States. Thyroid 2007; 17: 1235-1242.
18. Bilimoria KY, Bentrem DJ, Ko CY, et al.: Extent of surgery affects survival for papillary thyroid cancer. Ann Surg 2007; 246: 375-381; discussion 381-374.
19. Shaha A:, Selective surgical management of well-differentiated thyroid cancer. Ann N Y Acad Sci 2008; 1138: 58-64.
20. Hay ID:, Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma. J Surg Oncol 2006; 94: 692-700.
21. Podnos YD, Smith DD, Wagman LD, et al.: Survival in patients with papillary thyroid cancer is not affected by the use of radioactive isotope. J Surg Oncol 2007; 96: 3-7.
22. Busaidy NL, Habra MA, Vassilopoulou-Sellin R:, Chapter 38. Endocrine malignancies. In:, Kantarjian HM, Wolff RA, Koller CA, editors. The MD Anderson Manual of Medical Oncology. New York: McGraw-Hill; 2011.
23. Giovanella L, Ceriani L, Ghelfo A, et al.: Thyroglobulin assay 4 weeks after thyroidectomy predicts outcome in low-risk papillary thyroid carcinoma. Clin Chem Lab Med 2005; 43: 843-847.
24. Miyauchi A, Kudo T, Miya A, et al.: Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. Thyroid 2011; 21: 707-716.
25. Pelizzo MR, Boschin IM, Toniato A, et al.: Papillary thyroid carcinoma: 35-year outcome and prognostic factors in 1858 patients. Clin Nucl Med 2007; 32: 440-444.
26. Welch Dinauer CA, Tuttle RM, Robie DK, et al.: Clinical features associated with metastasis and recurrence of differentiated thyroid cancer in children, adolescents and young adults. Clin Endocrinol 1998; 49: 619-628.
27. Thompson GB, Hay ID:, Current strategies for surgical management and adjuvant treatment of childhood papillary thyroid carcinoma. World J Surg 2004; 28: 1187-1198.
28. Grigsby PW, Gal-or A, Michalski JM, et al.: Childhood and adolescent thyroid carcinoma. Cancer 2002; 95: 724-729.
29. Chow SM, Law SC, Mendenhall WM, et al.: Differentiated thyroid carcinoma in childhood and adolescence-clinical course and role of radioiodine. Pediatr Blood Cancer 2004; 42: 176-183.
30. La Quaglia MP, Black T, Holcomb GW III, et al.: Differentiated thyroid cancer: Clinical characteristics, treatment, and outcome in patients under 21 years of age who present with distant metastases. A report from the Surgical Discipline Committee of the Children's Cancer Group. J Pediatr Surg 2000; 35: 955-959; discussion 960.
31. Jarzab B, Handkiewicz-Junak D, Wloch J:, Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: A qualitative review. Endocr Relat Cancer 2005; 12: 773-803.
32. Zebrack BJ:, Psychological, social, and behavioral issues for young adults with cancer. Cancer 2011; 117: 2289-2294.
33. Vriens MR, Moses W, Weng J, et al.: Clinical and molecular features of papillary thyroid cancer in adolescents and young adults. Cancer 2011; 117: 259-267.
34. Hoelzer S, Steiner D, Bauer R, et al.: Current practice of radioiodine treatment in the management of differentiated thyroid cancer in Germany. Eur J Nucl Med 2000; 27: 1465-1472.
35. Bal CS, Kumar A, Pant GS:, Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: A randomized clinical trial in 509 patients. J Clin Endocrinol Metab 2004; 89: 1666-1673.
36. Kukulska A, Krajewska J, Gawkowska-Suwinska M, et al.: Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): Prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi. Thyroid Res 2010; 3: 9.
37. Kim EY, Kim TY, Kim WG, et al.: Effects of different doses of radioactive iodine for remnant ablation on successful ablation and on long-term recurrences in patients with differentiated thyroid carcinoma. Nucl Med Commun 2011; 32: 954-959.
38. Maenpaa HO, Heikkonen J, Vaalavirta L, et al.: Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: A randomized study. PLoS ONE 2008; 3: e1885.
39. Hackshaw A, Harmer C, Mallick U, et al.: 131I activity for remnant ablation in patients with differentiated thyroid cancer: A systematic review. J Clin Endocrinol Metab 2007; 92: 28-38.
40. Mallick U, Harmer C, Hackshaw A:, The HiLo trial: A multicentre randomised trial of high- versus low-dose radioiodine, with or without recombinant human thyroid stimulating hormone, for remnant ablation after surgery for differentiated thyroid cancer. Clin Oncol (R Coll Radiol) 2008; 20: 325-326.
41. Pacini F, Molinaro E, Castagna MG, et al.: Ablation of thyroid residues with 30 mCi (131)I: A comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 2002; 87: 4063-4068.
42. Pacini F, Ladenson PW, Schlumberger M, et al.: Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: Results of an international, randomized, controlled study. J Clin Endocrinol Metab 2006; 91: 926-932.
43. Luster M, Handkiewicz-Junak D, Grossi A, et al.: Recombinant thyrotropin use in children and adolescents with differentiated thyroid cancer: A multicenter retrospective study. J Clin Endocrinol Metab 2009; 94: 3948-3953.
44. Tuttle RM, Lopez N, Leboeuf R, et al.: Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function. Thyroid 2010; 20: 257-263.
45. de Keizer B, Hoekstra A, Konijnenberg MW, et al.: Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer. J Nucl Med 2004; 45: 1549-1554.
46. Kloos RT, Duvuuri V, Jhiang SM, et al.: Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma. J Clin Endocrinol Metab 2002; 87: 5817-5820.
47. Zettinig G, Hanselmayer G, Fueger BJ, et al.: Long-term impairment of the lacrimal glands after radioiodine therapy: A cross-sectional study. Eur J Nucl Med Mol Imaging 2002; 29: 1428-1432.
48. Tuttle RM, Leboeuf R, Robbins RJ, et al.: Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J Nucl Med 2006; 47: 1587-1591.
49. Mazzaferri EL:, Gonadal damage from 131I therapy for thyroid cancer. Clin Endocrinol 2002; 57: 313-314.
50. Ceccarelli C, Bencivelli W, Morciano D, et al.: 131I therapy for differentiated thyroid cancer leads to an earlier onset of menopause: Results of a retrospective study. J Clin Endocrinol Metab 2001; 86: 3512-3515.
51. Hoftijzer HC, Heemstra KA, Corssmit EP, et al.: Quality of life in cured patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 2008; 93: 200-203.
52. Giusti M, Sibilla F, Cappi C, et al.: A case-controlled study on the quality of life in a cohort of patients with history of differentiated thyroid carcinoma. J Endocrinol Invest 2005; 28: 599-608.
53. Sawka AM, Thabane L, Parlea L, et al.: Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: A systematic review and meta-analysis. Thyroid 2009; 19: 451-457.
54. Brown AP, Chen J, Hitchcock YJ, et al.: The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 2008; 93: 504-515.
55. de Vathaire F, Schlumberger M, Delisle MJ, et al.: Leukaemias and cancers following iodine-131 administration for thyroid cancer. Br J Cancer 1997; 75: 734-739.
56. Rubino C, de Vathaire F, Dottorini ME, et al.: Second primary malignancies in thyroid cancer patients. Br J Cancer 2003; 89: 1638-1644.
57. Sandeep TC, Strachan MW, Reynolds RM, et al.: Second primary cancers in thyroid cancer patients: A multinational record linkage study. J Clin Endocrinol Metab 2006; 91: 1819-1825.
58. Iyer NG, Morris LG, Tuttle RM, et al.: Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer 2011; 117: 4439-4446.
59. Berthe E, Henry-Amar M, Michels JJ, et al.: Risk of second primary cancer following differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2004; 31: 685-691.
60. Hall P, Holm LE, Lundell G, et al.: Tumors after radiotherapy for thyroid cancer. A case-control study within a cohort of thyroid cancer patients. Acta Oncol (Stockholm, Sweden) 1992; 31: 403-407.
61. Fallahi B, Adabi K, Majidi M, et al.: Incidence of second primary malignancies during a long-term surveillance of patients with differentiated thyroid carcinoma in relation to radioiodine treatment. Clin Nucl Med 2011; 36: 277-282.
62. Canchola AJ, Horn-Ross PL, Purdie DM:, Risk of second primary malignancies in women with papillary thyroid cancer. Am J Epidemiol 2006; 163: 521-527.
63. Lang BH, Lo CY, Wong IO, et al.: Impact of second primary malignancy on outcomes of differentiated thyroid carcinoma. Surgery 2010; 148: 1191-1196; discussion 1196-1197.
64. Ishikawa K, Noguchi S, Tanaka K, et al.: Second primary neoplasms in thyroid cancer patients. Jpn J Cancer Res 1996; 87: 232-239.
65. Schvartz C, Bonnetain F, Dabakuyo S, et al.: Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients. J Clin Endocrinol Metab 2012.
66. Hay ID, McConahey WM, Goellner JR:, Managing patients with papillary thyroid carcinoma: insights gained from the Mayo Clinic's experience of treating 2,512 consecutive patients during 1940 through 2000. Trans Am Clin Climatol Assoc 2002; 113: 241-260.
67. Chow SM, Law SC, Mendenhall WM, et al.: Papillary thyroid carcinoma: prognostic factors and the role of radioiodine and external radiotherapy. Int J Radiat Oncol Biol Phys 2002; 52: 784-795.
68. Tsang RW, Brierley JD, Simpson WJ, et al.: The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer 1998; 82: 375-388.
69. Sosa JA, Bowman HM, Tielsch JM, et al.: The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg 1998; 228: 320-330.
70. Saunders BD, Wainess RM, Dimick JB, et al.: Who performs endocrine operations in the United States ? Surgery 2003; 134: 924-931; discussion 931.
71. Tala H, Tuttle RM:, Contemporary post surgical management of differentiated thyroid carcinoma. Clin Oncol (R Coll Radiol) 2010; 22: 419-429.
72. Vaisman F, Shaha A, Fish S, et al.: Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer. Clin Endocrinol (Oxf) 2011.
73. Carling T, Carty SE, Ciarleglio MM, et al.: American thyroid association design and feasibility of a prospective randomized controlled trial of prophylactic central lymph node dissection for papillary thyroid carcinoma. Thyroid 2012; 22: 237-244.
74. Lang BH, Wong KP, Wan KY, et al.: Impact of routine unilateral central neck dissection on preablative and postablative stimulated thyroglobulin levels after total thyroidectomy in papillary thyroid carcinoma. Ann Surg Oncol 2012; 19: 60-67.
75. Laird AM, Gauger PG, Miller BS, et al.: Evaluation of postoperative radioactive iodine scans in patients who underwent prophylactic central lymph node dissection. World J Surg 2012; 36: 1268-1273.
76. Bonnet S, Hartl D, Leboulleux S, et al.: Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: Implications for radioiodine treatment. J Clin Endocrinol Metab 2009; 94: 1162-1167.
77. Tisell LE, Nilsson B, Molne J, et al.: Improved survival of patients with papillary thyroid cancer after surgical microdissection. World J Surg 1996; 20: 854-859.
78. Hughes DT, White ML, Miller BS, et al.: Influence of prophylactic central lymph node dissection on postoperative thyroglobulin levels and radioiodine treatment in papillary thyroid cancer. Surgery 2010; 148: 1100-1106; discussion 1006-1107.
79. Zetoune T, Keutgen X, Buitrago D, et al.: Prophylactic central neck dissection and local recurrence in papillary thyroid cancer: A meta-analysis. Ann Surg Oncol 2010; 17: 3287-3293.